Deep Ensemble for the Recognition of Malignancy (DERM)

DEVICE4 trials

Sponsors

Skin Analytics Limited

Conditions

Basal Cell CancerBasal Cell CarcinomaMalignant Skin Melanoma T0MelanomaMelanoma of SkinNon-melanoma Skin CancerSkin CancerSquamous Cell Cancer

Unknown Phase

DERM NMSC Validation Study

CompletedNCT04116983

Skin Analytics LimitedNon-melanoma Skin Cancer

Start: 2020-06-26End: 2022-03-16Updated: 2022-05-18

DERM Health Economics Study

CompletedNCT04123678

Skin Analytics LimitedMelanoma, Non-melanoma Skin Cancer

Start: 2020-02-26End: 2021-08-06Updated: 2021-08-13

DERM US and EU Validation Study

CompletedNCT05126173

Skin Analytics LimitedBasal Cell Carcinoma, Malignant Skin Melanoma T0, Squamous Cell Carcinoma

Start: 2022-03-15End: 2022-09-15Updated: 2023-06-28

How Consistent is the Output of DERM, When Used to Assess Images of Potentially Cancerous Skin Lesions.

CompletedNCT06654999

Skin Analytics LimitedBasal Cell Cancer, Melanoma of Skin, Skin Cancer +1

Start: 2024-12-18End: 2025-06-30Updated: 2025-07-09

Related Papers

Accuracy of an artificial intelligence as a medical device as part of a UK-based skin cancer teledermatology service

Frontiers in Medicine2024-03-2218 citations

Patient perspectives of artificial intelligence as a medical device in a skin cancer pathway

Frontiers in Medicine2023-11-1611 citations

Effectiveness of an image analyzing AI-based Digital Health Technology to identify Non-Melanoma Skin Cancer and other skin lesions: results of the DERM-003 study

Frontiers in Medicine2023-10-0620 citations